Implant Site Nexplanon Reaction?
Main Author: | |
---|---|
Publication Date: | 2015 |
Other Authors: | , , |
Format: | Article |
Language: | eng |
Source: | Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) |
Download full: | http://hdl.handle.net/10400.17/2407 |
Summary: | Nexplanon (Schering-Plough Limited/Merck Sharp & Dohme Limited (MSD)) is a long active reversible contraceptive method that provides effective contraception for 3 years. It consists of a single, flexible, rod-shaped implant, containing 68 mg etonogestrel. It is 4 cm long, consists of an ethylene vinyl acetate copolymer, a non-absorbable material, and also contains 15 mg of barium sulfate, which makes it visible by X-ray. We describe a case of a 39-year-old woman who experienced a local reaction to the barium sulfate in Nexplanon. She was given medical treatment, but only the removal of the implant resolved the symptoms. After removal there was gradual improvement and 72 h later the patient was asymptomatic. Allergic reaction to barium sulfate is extremely rare: until now, there have only been two cases associated with Nexplanon described in the literature. |
id |
RCAP_90e9dc9c6cdfbf878aea3adcb81c90fd |
---|---|
oai_identifier_str |
oai:repositorio.chlc.pt:10400.17/2407 |
network_acronym_str |
RCAP |
network_name_str |
Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) |
repository_id_str |
https://opendoar.ac.uk/repository/7160 |
spelling |
Implant Site Nexplanon Reaction?MAC GINMAC OBSBarium Sulfate/adverse effectsContraceptive Agents, Female/administration & dosageContraceptive Agents, Female/adverse effectsDesogestrel/adverse effectsDevice RemovalDrug Eruptions/etiologyDrug Implants/adverse effectsTreatment OutcomeNexplanon (Schering-Plough Limited/Merck Sharp & Dohme Limited (MSD)) is a long active reversible contraceptive method that provides effective contraception for 3 years. It consists of a single, flexible, rod-shaped implant, containing 68 mg etonogestrel. It is 4 cm long, consists of an ethylene vinyl acetate copolymer, a non-absorbable material, and also contains 15 mg of barium sulfate, which makes it visible by X-ray. We describe a case of a 39-year-old woman who experienced a local reaction to the barium sulfate in Nexplanon. She was given medical treatment, but only the removal of the implant resolved the symptoms. After removal there was gradual improvement and 72 h later the patient was asymptomatic. Allergic reaction to barium sulfate is extremely rare: until now, there have only been two cases associated with Nexplanon described in the literature.BMJ Publishing GroupRepositório da Unidade Local de Saúde São JoséPedroso, CMartins, IPalma, FMachado, AI2016-03-04T16:26:47Z20152015-01-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10400.17/2407eng10.1136/bcr-2014-206256info:eu-repo/semantics/openAccessreponame:Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)instname:FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologiainstacron:RCAAP2025-03-06T16:46:16Zoai:repositorio.chlc.pt:10400.17/2407Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireinfo@rcaap.ptopendoar:https://opendoar.ac.uk/repository/71602025-05-29T00:17:17.840826Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) - FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologiafalse |
dc.title.none.fl_str_mv |
Implant Site Nexplanon Reaction? |
title |
Implant Site Nexplanon Reaction? |
spellingShingle |
Implant Site Nexplanon Reaction? Pedroso, C MAC GIN MAC OBS Barium Sulfate/adverse effects Contraceptive Agents, Female/administration & dosage Contraceptive Agents, Female/adverse effects Desogestrel/adverse effects Device Removal Drug Eruptions/etiology Drug Implants/adverse effects Treatment Outcome |
title_short |
Implant Site Nexplanon Reaction? |
title_full |
Implant Site Nexplanon Reaction? |
title_fullStr |
Implant Site Nexplanon Reaction? |
title_full_unstemmed |
Implant Site Nexplanon Reaction? |
title_sort |
Implant Site Nexplanon Reaction? |
author |
Pedroso, C |
author_facet |
Pedroso, C Martins, I Palma, F Machado, AI |
author_role |
author |
author2 |
Martins, I Palma, F Machado, AI |
author2_role |
author author author |
dc.contributor.none.fl_str_mv |
Repositório da Unidade Local de Saúde São José |
dc.contributor.author.fl_str_mv |
Pedroso, C Martins, I Palma, F Machado, AI |
dc.subject.por.fl_str_mv |
MAC GIN MAC OBS Barium Sulfate/adverse effects Contraceptive Agents, Female/administration & dosage Contraceptive Agents, Female/adverse effects Desogestrel/adverse effects Device Removal Drug Eruptions/etiology Drug Implants/adverse effects Treatment Outcome |
topic |
MAC GIN MAC OBS Barium Sulfate/adverse effects Contraceptive Agents, Female/administration & dosage Contraceptive Agents, Female/adverse effects Desogestrel/adverse effects Device Removal Drug Eruptions/etiology Drug Implants/adverse effects Treatment Outcome |
description |
Nexplanon (Schering-Plough Limited/Merck Sharp & Dohme Limited (MSD)) is a long active reversible contraceptive method that provides effective contraception for 3 years. It consists of a single, flexible, rod-shaped implant, containing 68 mg etonogestrel. It is 4 cm long, consists of an ethylene vinyl acetate copolymer, a non-absorbable material, and also contains 15 mg of barium sulfate, which makes it visible by X-ray. We describe a case of a 39-year-old woman who experienced a local reaction to the barium sulfate in Nexplanon. She was given medical treatment, but only the removal of the implant resolved the symptoms. After removal there was gradual improvement and 72 h later the patient was asymptomatic. Allergic reaction to barium sulfate is extremely rare: until now, there have only been two cases associated with Nexplanon described in the literature. |
publishDate |
2015 |
dc.date.none.fl_str_mv |
2015 2015-01-01T00:00:00Z 2016-03-04T16:26:47Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10400.17/2407 |
url |
http://hdl.handle.net/10400.17/2407 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
10.1136/bcr-2014-206256 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
BMJ Publishing Group |
publisher.none.fl_str_mv |
BMJ Publishing Group |
dc.source.none.fl_str_mv |
reponame:Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) instname:FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia instacron:RCAAP |
instname_str |
FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) |
collection |
Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) |
repository.name.fl_str_mv |
Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) - FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia |
repository.mail.fl_str_mv |
info@rcaap.pt |
_version_ |
1833600473039372288 |